Blogs - Cadence

Home » Blogs

By Emily Anderson In Communications

Coming Full Circle: Why Rare Disease Work Feels Personal to Me

People often ask how I became so passionate about working in the rare disease space with healthcare providers, patients, and…

Communications

Beyond the Symptom: Lessons from the United in Hope PWS Conference

Communications Market Research Medical Communications

From Insight to Impact: The Critical Role of Medical Congresses in Advancing Drug Development

Communications Leadership

What is Conscious Organizational Development?

Communications Medical Communications

Cadence KOL Webinar: Advancing Hepatocellular Carcinoma Care

Communications

Understanding EcoVadis: Is It Right for Your Company?

Communications

Cadence Earns Platinum Medal from EcoVadis for Sustainability Performance

ALL CADENCE INSIGHTS

Coming Full Circle: Why Rare Disease Work Feels Personal to Me

Beyond the Symptom: Lessons from the United in Hope PWS Conference

From Insight to Impact: The Critical Role of Medical Congresses in Advancing Drug Development

What is Conscious Organizational Development?

Cadence KOL Webinar: Advancing Hepatocellular Carcinoma Care

Understanding EcoVadis: Is It Right for Your Company?

Cadence Earns Platinum Medal from EcoVadis for Sustainability Performance

ASCO 2024 Highlights: Advancing Cancer Care Through Innovation and Collaboration

Anticipating ASCO: FLEX trial and MammaPrint in Breast Cancer

Anticipating ASCO: MARIPOSA trial in Lung Cancer

Anticipating ASCO: IMROZ trial in Multiple Myeloma

Co-Founder Laura Smith: How Authenticity Contributes to the Bottom Line

Cadence Hosts HR+/HER2- Breast Cancer Treatment Webinar, 9:00 AM CT, May 8

Exploring Breakthroughs in Sarcomas and Rare Cancers: Highlights from ESMO Congress 2024

Co-Founder Sugata Biswas Featured at TEDxUTD, April 19, 2024

Integrated Services: A Unique Approach that Integrates Science, Market Research, and KOL Engagement Expertise

The Digital Doctor: AI Emerges as a Clinical Guide for Cancer Management

Creating Value in Business through Emotional Intelligence

Revolutionizing Medical Writing: Harnessing the Power of Artificial Intelligence

Navigating the Privacy Landscape: Essential Policies for GDPR Compliance

ASCO GU Symposium 2024: A Quest for Better Patient Outcomes

Building Bridges: The Cadence Approach to Authentic Business Connections

Privacy: What Every Small Business Should Know

The Basics of General Data Protection Regulations (GDPR): What Every Company Should Know about Managing Data

Navigating the ADHD Medication Shortage: Challenges and Impacts

Cadence Communications & Research Rated Outstanding for Ethics

The Compliance Conundrum

AI Basics: The Building Blocks of AI Magic

Mastering Collaboration with Key Opinion Leaders for Successful Partnerships

The Power of Predictive Insights: Cadence Communications & Research KOL Market Snapshot Reports

AI Decoded: A Non-Technical Look at Artificial Intelligence and Its Application in Pharma & Marketing Research

Operations: Considering the Human Factors

Building an Incredible Company Culture From the Ground Up: The Story of Cadence Communications & Research

Improving Patient Lives: Cadence Communications & Research Launches Syndicated Key Opinion Leader Reports

15 Years of Defying the Odds

Cultural Biases and Respondent Tendencies in International Market Research

Theory of Mind and the Top Five Things You Can do to Avoid Moderator-Likeability Bias

General Data Protection Regulation Compliance: Securing Data to Create Value

COVID-19 Background and Insights: Epidemiology

COVID-19 Background and Insights: Virology

Top 5 Ways to Make Your Virtual Meeting a Success

Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business

Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies

White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer

Client Testimonials

Clinical Case Forum

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

Take a Look Into Our Market Access Work

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

Act NOW!

Tips on Cultivating Vision in your Organization

Reflections on the Legacy of Dick Fordyce

Starbucks, Pumpkin Spice Latte and Why Medical Myths Persist in the Age of Information

The Cadence Concierge Experience

Meeting Planning Processes 101’s

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

What Does it Mean for a Vendor to be of Service?

Leveraging Innovation Centers to Re-prime the Development Pump!

What are the biggest concerns manufacturers have about the Sunshine Act?

Will the Sunshine Act eliminate bias from the US healthcare system?

Mixology…Blending Methodologies for Today’s Challenges

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL

Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML

Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy

Founder’s Blog: Why You Should Give a Damn about Your Vendor’s Culture

Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer

Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer

Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors

Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer

Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC

What can the Pharmaceutical industry do to re-prime its development pump?

Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution

How do we mix qualitative insight with quantitative research?

Why Cadence Achieved Status as One of Inc.’s Fastest-Growing Private Companies for Second Year in a Row!

The Forward March of Regress

What will be the impact of the ACA on cancer treatment?

Advice from Founder of Cadence Research, One of Inc.’s Fastest-Growing Private Companies in 2012